Acute Vulvovaginal Candidiasis Treatment Market, by Drug Type (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, and Others), by Route of Administration (Oral, Intravenous, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Dec 2020

Code : CMI4315

Pages :152

Formats :

Excel and PDF

Industry : Pharmaceutical

Acute Vulvovaginal Candidiasis Treatment MarketSize and Trends

The global acute vulvovaginal candidiasis treatment market is estimated to be valued at US$ 308.0 Mn in 2020 and is expected to exhibit a CAGR of 3.0% over the forecast period (2020-2027).

Figure 1: Global Acute Vulvovaginal Candidiasis Treatment Market Share (%) Analysis, By Drug Type, 2020

Increasing prevalence of acute vulvovaginal candidiasis is expected to drive growth of the global acute vulvovaginal candidiasis treatment market over the forecast period

Increasing incidence of acute vulvovaginal candidiasis among the population is expected to drive growth of the global market over the forecast period.

Increasing product launches for the treatment of vulvovaginal candidiasis is expected to drive growth of the acute vulvovaginal candidiasis treatment market over the forecast period

Market players are engaged in launching new products for the treatment of vulvovaginal candidiasis, which is expected to drive growth of the acute vulvovaginal candidiasis treatment market over the forecast period.

Global Acute Vulvovaginal Candidiasis Treatment Market - Impact of the Coronavirus (COVID-19) Pandemic

COVID-19 pandemic is expected to hamper growth of the global acute vulvovaginal candidiasis treatment market during the forecast period.

Figure 2: Global Acute Vulvovaginal Candidiasis Treatment Market (US$ Mn), by Region, 2020